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Abstract 
iv 
Jeremy Martinson, DPhil  
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Treatment-Emergent Resistance to Ceftolozane-Tazobactam   
Abigail McGartland Rubio, MPH  
University of Pittsburgh, 2020   
Abstract   
Background: Multidrug-resistant (MDR) Pseudomonas aeruginosa is a major public health 
threat. Treatment with ceftolozane-tazobactam improves patient outcomes compared to salvage 
therapy; however, resistance has emerged in ~15% of patients following courses ranging from 7 
to 53 days. Understanding the development and mechanisms of resistance in these difficult to treat 
MDR P. aeruginosa has public health importance. Our objective was to study the in vitro activity 
of alternative β-lactams in the setting of ceftolozane-tazobactam resistance.    
Methods: Isolates from 23 patients in whom ceftolozane-tazobactam resistance emerged were 
selected for analysis. Minimum inhibitory concentrations (MICs) were determined by standard 
broth microdilution in triplicate and interpreted by CLSI breakpoints. Mechanisms of resistance 
and relatedness of isolates were explored through whole-genome sequence (WGS) analysis in 15 
patients from whom baseline and post-treatment isolates were available.   
Results: 23 baseline and 32 post-treatment isolates were included. The median baseline 
ceftolozane-tazobactam MIC was 2 µg/mL (range: 0.5 – 8 µg/mL). 75%, 25%, 82.6%, and 83.3% 
of baseline isolates were non-susceptible to ceftazidime, ceftazidime-avibactam, imipenem, and 
piperacillin-tazobactam respectively. Following a median 16 (range: 3- 60) days of therapy, the 
median post-exposure ceftolozane-tazobactam MIC was 64 µg/mL (range: 8 – >256 µg/mL).  
100%, 72.7%, 69.6%, and 79.2% of post-treatment isolates were resistant to ceftazidime, 
ceftazidime-avibactam, imipenem, and piperacillin-tazobactam. The corresponding MIC 
v  
foldchanges were 4, 8, -2, and 0, respectively. Median imipenem-relebactam MICs did not change 
before or after treatment with ceftolozane-tazobactam (median= 2 µg/mL for both) and 16.7% 
were classified as resistant. WGS data revealed several mutations in ampC and ampR sequences.  
Discussion: Our findings show that resistance to ceftolozane-tazobactam impacts the 
susceptibility of alternative β-lactams. Cross resistance occurs with ceftazidime and 
ceftazidimeavibactam (median 4 and 8 fold MIC increase, respectively).  Imipenem MICs are 
decreased 2fold potentially demonstrating collateral sensitivity.  Piperacillin-tazobactam MICs 
were unchanged and isolates remained resistant. Importantly, imipenem-relebactam MICs were 
unchanged suggesting the mechanism of ceftolozane-tazobactam resistance may be due to 
structural changes in ampC.  WGS data showed a number of different mutations in both ampC and 
ampR. Certain mutations, such as F147L and mutations found in positions 234-244, were found to 
promote resistance to ceftolozane-tazobactam.    
vi 
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1.0 Background  
Pseudomonas aeruginosa is a common pathogen causing nosocomial infection. Antibiotic 
resistance in this bacterium results in multidrug-resistant (MDR) P. aeruginosa, which presents a 
major public health threat. 2.8 million antibiotic resistant infections occur in the United States 
every year, and 35,000 people will die as a result (Centers, 2019).  Additionally, it is important to 
note everyone is at risk of contracting antibiotic resistant infections.  However, certain populations, 
such as the elderly or immunocompromised persons, have a higher risk of contracting an antibiotic 
infection. The CDC released an antibiotic resistant threat report in 2019 which covers 18 different 
antibiotic resistant infections.  Each infection was given a classification as urgent threat, serious 
threat, concerning threat, or watch list.  Classifications of urgent and serious threat require the most 
attention and immediate action. MDR P. aeruginosa was listed as a serious threat in this report.  
This was listed as a serious threat, because in 2019 there were 32,600 cases, and 2,700 deaths due 
to MDR P. aeruginosa, as well as $767 million in attributable health care costs (Centers, 2019).    
Patients with MDR P. aeruginosa infections represent a significant therapeutic challenge 
to clinicians. A new antibiotic combination, ceftolozane-tazobactam has provided new hope in 
treating MDR P. aeruginosa. Treatment with ceftolozane-tazobactam improves patient outcomes 
compared to salvage therapy (Haidar, 2017; Shortridge, 2017; van Duin, 2016).  At UPMC 
Presbyterian, treatment of MDR P. aeruginosa with ceftolozane-tazobactam resulted in 30-day 
clinical cure and survival rates of 55% and 77% respectively. However, on balance with these 
encouraging results, resistance to ceftolozane-tazobactam emerged in ~15% of patients following 
treatment courses ranging from 7 to 53 days. This novel resistance seen in isolates was found to 
2  
have mutations ampC and ampR sequences (Haidar, 2017).  In MDR P. aeruginosa ampC is a 
chromosomally encoded and inducible protein.  AmpR is also chromosomally encoded in MDR P. 
aeruginosa and can induce ampC (Livermore, 1982; Torrens, 2019). These are proteins of interest 
because ampC is capable of drug hydrolysis. Ceftolozane-tazobactam was selected as a therapeutic 
measure for MDR P. aeruginosa because it has a bulky R2 side chain (Barnes, 2018). This side 
chain makes ceftolozane-tazobactam too large to fit into the binding site and be hydrolyzed by 
ampC. Understanding the development and mechanisms of resistance in these difficult to treat 
MDR P. aeruginosa has public health importance as it could increase overall clinical cure and 
survival rates by identifying optimal treatment regimens and new therapeutic targets.     
Additionally, it is important to understand cross resistance or collateral sensitivity that 
arises in light of resistance. Cross resistance occurs when isolates develop resistance to the 
treatment antibiotic and therefore causes resistance to other antibiotics to develop that were not 
used for treatment.  Whereas, collateral sensitivity is when resistance develops to the treatment 
antibiotic and causes increased susceptibility to other antibiotics.  Ceftolozane-tazobactam has the 
same backbone as ceftazidime but also has the bulky R2 side chain (Barnes, 2018).  Therefore, 
testing ceftazidime for cross resistance is imperative to guide therapeutic measures for clinicians 
and promote public health. Collateral sensitivity can present a unique opportunity to clinicians.  
While ceftolozane-tazobactam resistance develops mutations occurring in ampC optimize 
ceftolozane-tazobactam as the substrate. Therefore, carbapenems with a chemically dissimilar 
structure might become less optimal substrates for ampC hydrolysis.  As a result, collateral 
sensitivity could occur in carbapenems imipenem and piperacillin-tazobactam.    
              Imipenem-relebactam is a novel carbapenem-b-lactamase inhibitor combination that was 
FDA approved in July 2019. Relebactam has been shown to have activity agains ampC and 
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potentially against mutated ampC (Karaiskos, 2019).  Therefore, imipenem-relebactam 
might provide a novel therapeutic option for clinicians treating ceftolozane-tazobactam resistant 
MDR P. aeruginosa.
1.1 Hypotheses   
1.1.1  Cephalosporins  
         I hypothesize the development of ceftolozane-tazobactam resistance in MDR P. aeruginosa 
isolates causes at least 4-fold increases in ceftazidime and ceftazidime-avibactam MICs due to 
structural similarities between ceftolozane and ceftazidime.   
1.1.2  Carbapenems   
         I hypothesize the development of ceftolozane-tazobactam resistance in MDR P. aeruginosa 
isolates causes at least 4-fold decreases in imipenem and piperacillin-tazobactam MICs due to 
mutations in ampC.   
1.1.3  Imipenem-relebactam  
      I hypothesize imipenem-relebactam will retain potent in vitro activity against isolates 
before and after treatment with ceftolozane-tazobactam due to relebactam’s activity against 
ampC.  
4  
1.1.4  AmpC 
I hypothesize that mutations in ampC are responsible for ceftolozane-tazobactam resistance 
in MDR P. aeruginosa.    
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2.0 Methods   
2.1 MIC Study   
2.1.1  Screening   
This was a retrospective cohort study of an initial 28 patients with MDR P. aeruginosa 
infections treated with >72 hours of ceftolozane-tazobactam from August 2015 to May 2019. 
Patients were screened for development of ceftolozane-tazobactam resistance.  Development of 
resistance was identified by measuring ceftolozane-tazobactam MICs using broth microdilution 
(BMD) reference methods as recommended by the Clinical Laboratory Standard Institute (CLSI) 
methods. Briefly, 96-well plates were used to create doubling dilutions of ceftolozane-tazobactam  
from 0.25-256 µg/mL with tazobactam at a fixed concentration of 4 µg/mL. 
Ceftolozanetazobactam MICs were measured in triplicate and susceptible, intermediate, and 
resistant MICs were defined according to CLSI breakpoints. Quality control (QC) strains E. coli 
ATCC 25922 and P. aeruginosa ATCC 27853 were used throughout. All QCs were in acceptable 
ranges. Nonsusceptible was defined as an isolate with an MIC  ³8 µg/mL. From the initial 28 
patients, 23 patients were selected for this study based on the following inclusion criteria: the 
patient must have been infected with P. aeruginosa, treated with ceftolozane-tazobactam, had a 
baseline isolate that was collected prior to treatment with ceftolozane-tazobactam, and had a 
nonsusceptible isolate collected post-exposure. Each patient had one baseline and at least one 
postexposure isolate.    
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Relatedness of baseline and post-exposure isolates were compared by whole genome sequence  
(WGS) analysis.  Post-exposure isolates were defined as those collected during or post treatment.  
Additionally, individual isolates were removed from analysis if WGS did not identify them as P. 
aeruginosa, or if they were susceptible to ceftolozane-tazobactam post-exposure.  The resulting 
study cohort was comprised of 23 patients with 23 baseline isolates and 32 post-exposure 
isolates.     
2.1.2  Susceptibility Testing   
A susceptibility profile was developed for the 55 isolates.  MICs were measured as 
described previously. Ranges tested for all isolates included Ceftazidime 0.5-512 µg/mL, 
ceftazidime-avibactam 0.25-256 µg/mL, ceftolozane-tazobactam 0.25-256 µg/mL, imipenem  
0.03-32 µg/mL, Imipenem-relebactam 0.03-32 µg/mL and piperacillin-tazobactam 0.5-512 µg/mL 
(avibactam, relebactam, and tazobactam tested at a fixed concentration of 4 µg/mL).    
2.1.3  Analysis    
Consensus MICs for each isolate were used for analysis. Consensus was identified for each 
drug, using the modal value when possible, and when not, the median of the triplicate tests was 
used. MIC fold-changes were calculated for each patient from baseline to post-exposure for each 
drug. Fold-changes were used to assess changes in susceptibility that develop in response to 
development of ceftolozane-tazobactam resistance.  Median fold-changes were identified for each 
drug in order to determine collateral sensitivity and cross resistance.    
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2.2 WGS Study   
2.2.1  Isolate Selection   
 A total of 39 isolates, 16 baseline and 23 post-exposure, from 15 patients were sent to the 
Kreiswirth Lab for WGS. Patients selected for WGS had large ceftolozane-tazobactam 
foldchanges, reliable ceftolozane-tazobactam treatment dates, and post-exposure isolates collected 
in close proximity to the treatment dates.     
2.2.2  Analysis   
Raw WGS data were received and examined for mutations in ampC and ampR protein 
sequences. PAO1 was used as the reference wild-type strain.  Any amino acid variation from the 
wild-type sequence was recorded as a mutation.  Mutations of interest were defined as mutations 
that arose in post-exposure isolates but were not present in baseline isolates for that patient.  
Relatedness of isolates was assessed using data received on sequence type (ST) and single 
nucleotide polymorphisms (SNP) variation.  Isolates with the same ST and £300 SNP variations 
were considered to be related.  If only ST or SNP data were available, one was considered sufficient 
to assess relatedness.      
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3.0 Results   
3.1 MIC Study   
 MIC  screening  revealed  that  patients  readily  developed  resistance  to  
ceftolozanetazobactam.  Baseline isolates had a median MIC of 2 µg/mL (range: 0.5-8 µg/mL) and 
postexposure isolates had a median MIC of 64 µg/mL (range: 8-512 µg/mL). Figure 1 shows the 
MIC distributions between baseline and post-exposure isolates. Ceftolozane-tazobactam MICs 
increased a median of 32-fold from baseline to post-exposure. Figure 2 shows MIC fold-changes— 
approximately a normal distribution.      
 
   
 
Figure 2: C/T MIC Fold-Changes   
  
Figure 1: Ceftolozane -tazobactam (C/T) Baseline and Post -exposure MIC frequencies  
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Isolates were tested for cross resistance to cephalosporins, ceftazidime and 
ceftazidimeavibactam.  Median MICs for baseline isolates against ceftazidime and 
ceftazidimeavibactam were 32 and 4 µg/mL respectively (ranges: 1-256 µg/mL; 1-32 µg/mL). 
Post-exposure isolates had a median ceftazidime and ceftazidime-avibactam MICs of 128 and 64 
µg/mL respectively (ranges: 32-1024 µg/mL; 4-512 µg/mL). Resulting median MIC fold-changes 
for ceftazidime and ceftazidime-avibactam were 4 and 8 respectively.  All MIC fold-changes are 
shown in Figures 3 and 4; both have approximately normal distributions.  Outliers were seen at a 
fold-change of 512 for ceftazidime and -4 for ceftazidime-avibactam. Additionally, 73.9% and 
26.1% of baseline isolates were non-susceptible to ceftazidime and ceftazidime-avibactam, 
respectively, compared to 100% and 71.9% of post-exposure isolates, respectively. Figure 5 shows 
the MIC fold-changes of cephalosporins compared to ceftolozane-tazobactam.     
 
Figure 3: Ceftazidime (CAZ) MIC Fold-Changes   
   
 
Figure 4: Ceftazidime-avibactam (CZA) MIC Fold-Changes   
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Figure 5: MIC Fold-Changes for Ceftolozane-tazobactam vs. Cephalosporins   
   
Piperacillin-tazobactam and imipenem were tested for collateral sensitivity. Baseline 
isolates had median MICs of 128 and 16 µg/mL for piperacillin-tazobactam and imipenem 
respectively (ranges: 1-512 µg/mL; 0.12-32 µg/mL). Comparatively, post-exposure isolates had 
median MICs of 32 and 2 µg/mL (ranges: 4-1024 µg/mL; 0.5-64 µg/mL).  Median MIC 
foldchanges were 0 and -2 for piperacillin-tazobactam and imipenem, respectively. Figures 6 and 
7 show MIC fold-changes for piperacillin-tazobactam and imipenem.  Both piperacillintazobactam 
and imipenem had a nearly bimodal distribution. Baseline isolates were found to be 82.6% and 
81.8% non-susceptible to piperacillin-tazobactam and imipenem respectively; whereas 
postexposure isolates were 84.4% and 50% non-susceptible.  Figure 8 displays MIC fold-changes 
of carbapenems compared to ceftolozane-tazobactam.   
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Figure 6: Piperacillin-tazobactam (P/T) MIC Fold-Changes    
   
 
Figure 7: Imipenem (IMI) MIC Fold-Changes   
   
 
Figure 8: MIC Fold-Changes for Ceftolozane-tazobactam vs. Carbapenems   
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were found to be 2 µg/mL for both baseline and post-exposure isolates (ranges: 0.06-16 µg/mL; 
0.25-16 µg/mL). The resulting fold-change was 0. 21.7% of baseline isolates were resistant to 
imipenem-relebactam compared to 12.5% of post-exposure isolates. Figure 9 shows all 
foldchanges and shows approximately a normal distribution.     
 
Figure 9: Imipenem-relebactam MIC Fold-Changes   
   
Figures 10 and 11 show of baseline and post-exposure MICs for each drug compared to 
ceftolozane-tazobactam. The red bar denotes the median MIC for each respective category.    
   
   
Figure 10: MICs Baseline (B) to Post-exposure (P) and their medians denoted by the red lines   
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Figure 11: MICs Baseline (B) to Post-exposure (P) and their medians denoted by the red lines   
3.2 WGS Study   
Isolates from 14 of 15 patients had the same ST and were within 300 SNP variations and 
were therefore considered to be related. Median SNP variation was 7 between baseline and 
postexposure isolates (range 0-291). Patient 2 had SNP variations of 22,953 and 22,956 between 
baseline and post-exposure isolates and was excluded from further analysis due to lack of a related 
baseline isolate. Patient 9 had two baseline isolates, however only one baseline isolate was 
considered to be related to all of the post-exposure isolates.  One baseline isolate from patient 9 
was >300 SNP variations from a post-exposure isolate.    
Four patients had mutations in ampR, which were found in both the baseline and 
postexposure isolates.  All 14 patients had mutations in ampC protein sequence. The most frequent 
mutation was T105A which was found in 87.1% of isolates.  Other common mutations included   
R79Q, G391A, and F147L.  Table 1 shows the full list of mutations and MIC values for each drug.    
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Mutations of interest have been bolded. Additionally, other beta-lactamases (BL’ases) were 
explored in WGS analysis.  All isolates had some other BL’ases the most common was OXA-50.   
No isolate had metallo-beta-lactamases.   
Table 1: WGS Data   
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Only patient 2 had a mutation of interest in the ampR sequence, however this could be due 
to the non-relatedness of the baseline isolate and therefore was not considered further for 
analysis.  In 11 patients at least one mutation of interest was identified in the ampC sequence.    
Patient 1, 16, and 20 had no change in mutations from baseline to post-exposure isolates.  
However, these patients had a small ceftolozane-tazobactam fold-change of 4, 4, and 2-fold 
increase.  The post-exposure MIC was 8 µg/mL which is 8-fold below the median 
ceftolozanetazobactam MIC (64 µg/mL). Mutation F147L and G183D were both found in 3 
patients each and were the most frequent mutations of interest.  In patients 18 and 13 F147 was 
the only mutation of interest identified and resulted in 64 and 256-fold increase. In patient 4 F147 
and G183D were the mutations of interest and resulted in an 8-fold increase.  Patient 25 had 
G183D as the only mutation of interest and experienced a 32-fold increase.  Patient 9 had  
G183D and 243Gins (insertion) as the mutations of interest and resulted in a 128-fold increase.   
Additionally, patient 8 had a mutation at position 183, mutation G183R, and they experienced a 
64-fold increase. Other notable mutations of interest occurred between positions 234-244. 
Patients 3, 7, 9, 10, 19 all had mutations of interest within these positions. MIC changes were 
also observable in Table 1. The changes discussed in previous hypothesis can be seen in a 
molecular context. Patient 9 and 25 are important examples.  Patient 9 has observable stepwise 
MIC increases in ceftolozane-tazobactam, ceftazidime, and ceftazidime-avibactam, and decreases 
in piperacillintazobactam and imipenem that occur with mutation acquisition.  Patient 25 is 
notable because the final isolate loses the mutation of interest and has a similar MIC 
susceptibility profile as the baseline isolate.    
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4.0 Discussion    
4.1 Cephalosporins    
P. aeruginosa readily developed ceftolozane-tazobactam resistance in infected patients. 
This resistance development led to cross resistance in cephalosporins.  Cross resistance is 
extremely problematic when considering therapeutic options.  When clinicians consider alternative 
treatments to accommodate resistance, they must also be aware of potential cross reactivity in order 
to prescribe effective treatment.  Ceftazidime exhibited a 4-fold increase from baseline to 
postexposure isolates and ceftazidime-avibactam exhibited an 8-fold increase.  Results shown in 
this study support the hypothesis that when ceftolozane-tazobactam resistance develops in MDR   
P. aeruginosa isolates, ceftazidime and ceftazidime-avibactam MICs will increase at least 4-fold.  
The 4-fold change was selected as the breakpoint change to confirm cross resistance because 
changes 2-fold or less could be due to random error.   In addition, baseline isolates were 75% and 
25% non-susceptible to ceftazidime and ceftazidime-avibactam which increased to 100% and 
72.7% in post-exposure isolates.  These data confirm cross resistance was occurring in both 
ceftazidime and ceftazidime-avibactam and therefore these antibiotics would not be good 
therapeutic options for clinicians.  Figure 5 visually represents both ceftazidime and 
ceftazidimeavibactam trend together with ceftolozane-tazobactam. This also suggests avibactam 
is not an effective inhibitor drug combination.  Comparatively, Figure 10 which has the MIC values 
and medians, shows trends are similar between baseline and post-exposure isolates for ceftazidime 
and ceftazidime-avibactam.  There were outliers in the data: patient 5 had a 512-fold increase in 
ceftazidime and patient 23 had a 4-fold decrease in ceftazidime-avibactam. Patient 5 also had the 
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largest fold-change in ceftolozane-tazobactam (512-fold increase), which could be responsible for 
the outlier value in ceftazidime.  Patient 23 was resistant to ceftazidime-avibactam at baseline but 
decreased to susceptible in the post-exposure isolate.    
4.2 Carbapenems   
Piperacillin-tazobactam had a median of 0-fold change from baseline to post-exposure 
isolates while imipenem had a median 2-fold decrease.  However, both drugs had nearly bimodal 
distribution. Considering this, roughly 50% of patients supported my hypothesis when 
ceftolozanetazobactam resistance develops in MDR P. aeruginosa isolates, piperacillintazobactam 
and imipenem MICs will decrease at least 4-fold, while roughly 50% did not.  There was not a 
uniform response to ceftolozane-tazobactam resistance development. These carbapenems were 
selected because as ampC mutates to hydrolyze ceftolozane-tazobactam, piperacillin-tazobactam 
and imipenem become less optimal substrates for ampC. As less optimal substrates for ampC 
piperacillin-tazobactam and imipenem, might demonstrated collateral sensitivity.  Again, roughly 
50% of patients demonstrated collateral sensitivity.  Most patients that fell outside of the 
hypothesized fold-change were the same for piperacillin-tazobactam and imipenem. Additionally, 
all patients with ampR mutations fell outside the hypothesis fold-change range. These data suggest 
there is some molecular similarity between patients outside the hypothesis range.  However, there 
was not a single commonality observed in all of the patients that fell outside the hypothesis range.  
As a result, further testing is needed to uncover the genetic reasons for some patients having a 
positive fold-change compared to those that had a negative fold-change.    
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4.3 Imipenem-relebactam    
Imipenem-relebactam maintained potent in vitro activity between baseline and 
postexposure isolates.  This was supported by both fold-change data and median MICs: no 
foldchange was observed, and the median MIC remained 2 µg/mL for baseline and post-exposure 
isolates. Additionally, only 21.7% of baseline isolates were found to be resistant to 
imipenemrelebactam, and only 12.5% of post-exposure isolates were resistant. Figure 11 visually 
represents how MICs remain unchanged despite development of ceftolozane-tazobactam 
resistance. These data support that relebactam has activity against ampC and a mutated ampC, and 
that imipenemrelebactam may be a viable therapeutic option for patients with ceftolozane-
tazobactam resistant MDR P. aeruginosa.   
4.4 AmpC   
4.4.1  Relatedness   
14 of 15 patients were considered to be related and the resulting post-exposure isolates 
likely evolved from the baseline isolates.  Patient 2 was removed from analysis, because they had 
no baseline that was related to the two post-exposure isolates.  No assumptions can be made about 
mutations in ampC or ampR in patient 2 that yield ceftolozane-tazobactam resistance. Patient 9 had 
two baselines however the post-exposure isolates likely evolved from one baseline isolate due to 
SNP variations. Therefore, assumptions about ampC and ampR mutations will be based on the 
more related baseline to the post-exposure isolates.   
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4.4.2  Mutations  
Several different mutations were identified in ampC and ampR protein sequences. AmpR 
acts as a promotor for ampC and therefore was essential to examine mutation in the ampR sequence 
as it ultimately would affect the expression of the ampC protein (Livermore, 1982; Torrens, 2019).   
Other BL’ases were explored in order to identify if any isolates had metallo-beta-lactamases.   
Metallo-beta-lactamases have been shown to confer ceftolozane-tazobactam resistance (Karaiskos, 
2019; Livermore, 2017). Therefore, it was necessary to rule out metallo-betalactamases as the 
agent conferring ceftolozane-tazobactam resistance.  Since no isolates had metallo-betalactamases 
it can be assumed a different agent is responsible for this resistance development.    
In 11 patients, at least one mutation of interest was identified in the ampC sequence.  
Notable mutations of interest were observed at F147L, position 183, and positions 234-244.  
Position 183 had two different mutations G183D and G183R. Therefore, it can be assumed position 
183 is important in development of ceftolozane-tazobactam resistance.  A previous study had found 
that the mutation G183D was responsible for ceftolozane-tazobactam resistance in their isolates 
(MacVane, 2017).  Similarly, positions 234-244 had different mutations.  These positions might 
fall in the omega loop of the ampC protein (Berrazeg, 2015).  The omega loop is a known hotspot 
for mutations.  Any mutations that occur here often effect the active site of ampC, therefore altering 
the overall function of ampC.  However, further research is still needed into the importance of 
positions 234-244 to understand how it promotes ceftolozane-tazobactam resistance.  Lastly, the 
largest fold-changes that occurred (256-fold increase) were F147L and deletion 237-243.  This 
suggests that these two mutations are of particular interest in future studies.  These data 
support the hypothesis that mutations in ampC are responsible for ceftolozane-tazobactam 
resistance in MDR P. aeruginosa.
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4.5 Conclusions  
These data supported all four of my hypotheses.  Cross resistance was evident between 
ceftazidime and ceftazidime-avibactam and ceftolozane-tazobactam.  Therefore, clinicians should 
not use ceftazidime or ceftazidime-avibactam to treat these MDR P. aeruginosa isolates.  Collateral 
sensitivity was also evident in roughly half of patients for piperacillin-tazobactam and imipenem.  
There were bimodal distributions in piperacillin-tazobactam and imipenem which showed a non-
uniform response to ceftolozane-tazobactam resistance development.  More molecular research is 
necessary to identify commonalities to the isolates that responded as hypothesized compared to 
those isolates that responded differently than hypothesized.  Additionally, imipenem-relebactam 
had potent in vitro activity against isolates before and after treatment with ceftolozane-tazobactam.  
Imipenem-relebactam is an effective treatment method for MDR P. aeruginosa isolates.  Lastly, in 
11 of 14 patients a mutation of interest was found in ampC, suggesting a mutated ampC is 
responsible for ceftolozane-tazobactam resistance.   
However, these data also leave more questions.  Moving forward I wish to recreate 
mutations seen in these isolates into the PAO1 strain.  This method will allow me to use Koch 
postulates to further support my hypotheses.  After recreating these mutations, I will observe if 
similar resistance and fold-changes occur.  I hypothesize creating mutant ampC in isolates will 
yield ceftolozane-tazobactam resistant MICs due to these mutations being found in resistant 
ceftolozane-tazobactam isolates.   
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